Oxford Biomedica is a gene and cell therapy group focused on developing treatments for serious diseases based around its FDA approved lentiviral vector delivery platform. The Company leverages this platform to develop in vivo and ex vivo products in-house and with global Pharmaceutical and Biotech partners and has created it's own portfolio of gene and cell therapy product candidates.

CMD 2025

H2 2025

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oxford Biomedica PLC (OXB LN)

CMD 2025

H2 2025

Jefferies London Healthcare Conference 2025

Stifel 2025 Healthcare Conference

H1 2025

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)